Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2331 - Prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancers (TNBC) treated with neoadjuvant chemotherapy (NAC)


10 Oct 2016


Poster display


Carmen Herrero-Vicent


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


C. Herrero-Vicent1, A. Guerrero1, J. Gavilá1, F. Gozalbo2, S. Blanch1, A. Hernández1, S. Sandiego1, A. Calatrava2, V. Guillem1, A. Ruiz1

Author affiliations

  • 1 Medical Oncology, Fundación Instituto Valenciano de Oncología, 46008 - Valencia/ES
  • 2 Pathology, Fundación Instituto Valenciano de Oncología, 46008 - Valencia/ES


Abstract 2331


Recent clinical studies have evaluated TILs in TNBC patients(pts) with different methodological approaches. The aim is to analyse the predictive and prognostic value of TIL following the recommendations for TILs Evaluations in Breast Cancer(BC) by an International TIL Working Group.


Using our BC database with 756 pts, we identified 164 TNBC treated with NAC between 1998-2015. Evaluation of TILs was following a standardized methodology for visual assessment on hematoxylin-eosin sections and TILs were quantitated in deciles. We categorized lymphocyte-predominant BC (LPBC) cutoff according to a receiver operating characteristic (ROC) curve. The primary endpoint was predictive value of TILs to NAC and secondary endpoint was disease-free survival (DFS). Kaplan-Meier curves were used to summarize DFS, and curves were compared with a log-rank test. Univariate and multivariate Cox models were used to generate hazard ratios (HR) for determining associations between variables and DFS.


We categorized LPBC as the involving > 40% TIL stroma. Pts were divided in subgroups:58 pts (35.4%) with LPBC and 106 pts (64.6%) non-LPBC. Main pts' characteristics are listed in Table 1. We identify different pathological complete response (pCR) to anthracycline and taxane-based NAC; LPBC 88% pCR vs non-LPBC 9% pCR, p = 0.001. At a median follow-up of 78 months, LPBC was associated with better DFS; the 3-year Kaplan-Meier estimates for DFS were 2 % and 30% in LPBC and non-LPBC, respectively p = 0.01. Univariate and multivariate analysis confirmed TIL to be an independent prognostic marker of DFS.

Patient's characteristics

Variable TILs level
  50 50 (86%) 90 (85%) p.270
Anthracycline + taxane 47 (81%) 98 (92%) p.570
pCR (ypT0/is, ypN0) 51 (88%) 10 (9%) p.001
Multifocal 4 (7%) 24 (22%) p.001
Conservative surgery 39 (67%) 43 (41%) p.001
Adjuvant Radiotherapy 51 (88%) 93 (88%) p.754
AC 12 (21%) 47(44%) p.078


TIL evaluation in TNBC pts could be included in the standard histopathological practise to identify two subgroups; LPBC with high pCR response to NAC and non-LPBC with worse prognosis. While our findings may not change current NAC options, it is a clinically relevant finding as TIL could be useful as an adjustment factor in future studies.

Clinical trial identification


Legal entity responsible for the study



Fundación Colegio de Médico de Valencia


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings